Skip to main
  1. Stocks
  2. REGENXBIO
  3. Forecast
RGNX

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Regenxbio is attractive because its lead RGX-202 program has a clear regulatory path, with rolling BLA submission beginning in 3Q26, completion in 1Q27, and potential accelerated approval in 2H27 backed by safety data from more than 60 patients and pivotal efficacy data. The company also has multiple near-term catalysts across its pipeline, including RGX-121 resubmission in 3Q26 and wet AMD topline results in 4Q26, while RGX-202 has shown >93% microdystrophin expression and clear functional improvement with a favorable safety profile. Financially, 2Q26 revenue reached $108.0M, net income was $22.7M, and pro forma cash rose to about $313M after a $100M AbbVie milestone and July 2026 financing, supporting operations into 4Q27.

Bears say

Regenxbio is facing a material setback after the FDA placed a clinical hold on RGX-121 following asymptomatic spine MRI findings in five CAMPSIITE participants, forcing a delay in the planned BLA resubmission and removing a key near-term commercialization opportunity. The fact that these patients were treated three to six years ago and that the prevalence and clinical significance of the findings remain unknown increases regulatory uncertainty, while the need for longer-term follow-up and additional data analysis weakens confidence in the asset’s benefit-risk profile. Although management says other Duchenne and retinal programs use different capsids and routes of administration, the hold underscores pipeline execution risk and suggests the company’s value remains highly dependent on unproven clinical readouts.

REGENXBIO (RGNX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

REGENXBIO (RGNX) Analyst Forecast & Price Prediction

Get the latest REGENXBIO (RGNX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in REGENXBIO (RGNX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 10 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


REGENXBIO (RGNX) Analyst Forecast & Price Prediction

Get the latest REGENXBIO (RGNX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in REGENXBIO (RGNX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover RGNX stock data and trends